TWST vs. IMCR, VCEL, DNLI, APGE, IOVA, RXRX, ACLX, ADMA, KYMR, and NVAX
Should you be buying Twist Bioscience stock or one of its competitors? The main competitors of Twist Bioscience include Immunocore (IMCR), Vericel (VCEL), Denali Therapeutics (DNLI), Apogee Therapeutics (APGE), Iovance Biotherapeutics (IOVA), Recursion Pharmaceuticals (RXRX), Arcellx (ACLX), ADMA Biologics (ADMA), Kymera Therapeutics (KYMR), and Novavax (NVAX). These companies are all part of the "biological products, except diagnostic" industry.
Twist Bioscience (NASDAQ:TWST) and Immunocore (NASDAQ:IMCR) are both mid-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, profitability, earnings, analyst recommendations, valuation, community ranking, institutional ownership, media sentiment and risk.
In the previous week, Immunocore had 9 more articles in the media than Twist Bioscience. MarketBeat recorded 15 mentions for Immunocore and 6 mentions for Twist Bioscience. Twist Bioscience's average media sentiment score of 1.22 beat Immunocore's score of 0.44 indicating that Twist Bioscience is being referred to more favorably in the media.
Twist Bioscience received 39 more outperform votes than Immunocore when rated by MarketBeat users. However, 71.43% of users gave Immunocore an outperform vote while only 56.69% of users gave Twist Bioscience an outperform vote.
Twist Bioscience has a beta of 1.64, indicating that its share price is 64% more volatile than the S&P 500. Comparatively, Immunocore has a beta of 0.92, indicating that its share price is 8% less volatile than the S&P 500.
Immunocore has a net margin of -22.60% compared to Twist Bioscience's net margin of -69.24%. Immunocore's return on equity of -16.54% beat Twist Bioscience's return on equity.
Twist Bioscience presently has a consensus target price of $42.50, suggesting a potential upside of 0.14%. Immunocore has a consensus target price of $81.85, suggesting a potential upside of 76.77%. Given Immunocore's higher possible upside, analysts plainly believe Immunocore is more favorable than Twist Bioscience.
Immunocore has higher revenue and earnings than Twist Bioscience. Immunocore is trading at a lower price-to-earnings ratio than Twist Bioscience, indicating that it is currently the more affordable of the two stocks.
84.5% of Immunocore shares are owned by institutional investors. 3.9% of Twist Bioscience shares are owned by company insiders. Comparatively, 9.1% of Immunocore shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Summary
Immunocore beats Twist Bioscience on 12 of the 18 factors compared between the two stocks.
Get Twist Bioscience News Delivered to You Automatically
Sign up to receive the latest news and ratings for TWST and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TWST and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Twist Bioscience Competitors List
Related Companies and Tools
